Cytoreduction with or without HIPEC: Where do we go from here?

[摘要] The American Cancer Society estimates that 97,220 new cases of colon cancer were diagnosed in the U.S. in 2018.1 Approximately 20 percent of these patients may develop peritoneal metastasis.2 For select patients with colon cancer and low-volume peritoneal metastasis, National Comprehensive Cancer Network (NCCN) guidelines recommend consideration of cytoreduction and intraperitoneal chemotherapy at experienced centers.3 This recommendation is supported by a 2003 randomized controlled trial in the Netherlands that demonstrated a doubling of survival (22.3 months versus 12.6 months) for patients treated with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C for 90 minutes compared with systemic 5-fluorouracil (FU) alone.4

[学科分类] 外科医学